Brainstorm Cell Therapeutics Stock Today
| BCLI Stock | USD 0.54 0.01 1.89% |
Performance9 of 100
| Odds Of DistressOver 71
|
Brainstorm Cell is trading at 0.54 as of the 23rd of April 2024. This is a 1.89 percent up since the beginning of the trading day. The stock's open price was 0.53. Brainstorm Cell has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. Equity ratings for Brainstorm Cell Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 24th of March 2024 and ending today, the 23rd of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 28th of August 2003 | Category Healthcare | Classification Health Care |
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York. The company has 68.34 M outstanding shares of which 1.34 M shares are currently shorted by private and institutional investors with about 1.19 trading days to cover. More on Brainstorm Cell Therapeutics
Moving together with Brainstorm Stock
| 0.61 | MRK | Merck Company Earnings Call This Week | PairCorr |
| 0.75 | OPT | Opthea | PairCorr |
Moving against Brainstorm Stock
| 0.71 | ANAB | AnaptysBio Financial Report 9th of May 2024 | PairCorr |
| 0.67 | GNTA | Genenta Science SpA Report 24th of April 2024 | PairCorr |
| 0.62 | JNJ | Johnson Johnson Aggressive Push | PairCorr |
| 0.61 | PCRX | Pacira Pharmaceuticals Financial Report 1st of May 2024 | PairCorr |
| 0.58 | ALKS | Alkermes Plc Financial Report 24th of April 2024 | PairCorr |
| 0.55 | MGTX | MeiraGTx Holdings PLC Financial Report 9th of May 2024 | PairCorr |
| 0.49 | EGRX | Eagle Pharmaceuticals | PairCorr |
Follow Valuation Options Odds of Bankruptcy
Financial Report 20th of May 2024
Brainstorm Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Brainstorm Cell's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Brainstorm Cell or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| President CoCEO | Chaim Lebovits | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering Brainstorm Cell report their recommendations after researching Brainstorm Cell's financial statements, talking to executives and customers, or listening in on Brainstorm Cell's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Brainstorm Cell Ther. The Brainstorm consensus assessment is calculated by taking the average forecast from all of the analysts covering Brainstorm Cell. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the analysis of Brainstorm Cell's profitability, liquidity, and operating efficiency, Brainstorm Cell Therapeutics may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter. Financial strength of Brainstorm Cell Ther is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Brainstorm Cell's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Brainstorm Cell's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Brainstorm Cell's financial leverage. It provides some insight into what part of Brainstorm Cell's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Brainstorm Cell Therapeutics (BCLI) is traded on NASDAQ Exchange in USA. It is located in 1325 Avenue of Americas, New York, NY, United States, 10019 and employs 29 people. Brainstorm Cell is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 36.36 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Brainstorm Cell's market, we take the total number of its shares issued and multiply it by Brainstorm Cell's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Brainstorm Cell Ther conducts business under Biotechnology sector and is part of Health Care industry. The entity has 68.34 M outstanding shares of which 1.34 M shares are currently shorted by private and institutional investors with about 1.19 trading days to cover.
Brainstorm Cell Therapeutics currently holds about 12.24 M in cash with (20.46 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.34.
Check Brainstorm Cell Probability Of Bankruptcy
Ownership AllocationBrainstorm Cell holds a total of 68.34 Million outstanding shares. Brainstorm Cell Therapeutics shows 12.8 percent of its outstanding shares held by insiders and 5.995999999999999 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Brainstorm Ownership Details
Brainstorm Stock Price Odds Analysis
Coming from a normal probability distribution, the odds of Brainstorm Cell jumping above the current price in 90 days from now is about 19.87%. The Brainstorm Cell Therapeutics probability density function shows the probability of Brainstorm Cell stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 1.7138 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Brainstorm Cell will likely underperform. Additionally, brainstorm Cell Therapeutics has an alpha of 0.9941, implying that it can generate a 0.99 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
Based on a normal probability distribution, the odds of Brainstorm Cell to move above the current price in 90 days from now is about 19.87 (This Brainstorm Cell Therapeutics probability density function shows the probability of Brainstorm Stock to fall within a particular range of prices over 90 days) .
Brainstorm Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Brainstorm Cell that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Brainstorm Cell's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Brainstorm Cell's value.| Instituion | Recorded On | Shares | |
| Northern Trust Corp | 2023-12-31 | 54.8 K | |
| Morgan Stanley - Brokerage Accounts | 2023-12-31 | 51.5 K | |
| Wells Fargo & Co | 2023-12-31 | 29.9 K | |
| Susquehanna International Group, Llp | 2023-12-31 | 24.8 K | |
| Group One Trading, Lp | 2023-12-31 | 24 K | |
| Barclays Plc | 2023-12-31 | 23.1 K | |
| Saxony Capital Management Llc | 2023-12-31 | 21.1 K | |
| Creative Planning Inc | 2023-12-31 | 21 K | |
| Janney Montgomery Scott Llc | 2023-12-31 | 20.5 K | |
| Vanguard Group Inc | 2023-12-31 | 1.4 M | |
| Blackrock Inc | 2023-12-31 | 466.4 K |
Brainstorm Cell Historical Income Statement
Brainstorm Cell Therapeutics Income Statement is one of the three primary financial statements used for reporting Brainstorm's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Brainstorm Cell Ther revenue and expense. Brainstorm Cell Income Statement primarily focuses on the company's revenues and expenses during a particular period.
As of now, Brainstorm Cell's Other Operating Expenses is increasing as compared to previous years. The Brainstorm Cell's current Cost Of Revenue is estimated to increase to about 278.2 K, while Gross Profit is forecasted to increase to (251.8 K). View More FundamentalsBrainstorm Stock Against Markets
Picking the right benchmark for Brainstorm Cell stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Brainstorm Cell stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Brainstorm Cell is critical whether you are bullish or bearish towards Brainstorm Cell Therapeutics at a given time. Please also check how Brainstorm Cell's historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Brainstorm Cell without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Alpha Finder Now
Alpha FinderUse alpha and beta coefficients to find investment opportunities after accounting for the risk |
| All Next | Launch Module |
Brainstorm Cell Corporate Directors
Brainstorm Cell corporate directors refer to members of a Brainstorm Cell board of directors. The board of directors generally takes responsibility for the Brainstorm Cell's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Brainstorm Cell's board members must vote for the resolution. The Brainstorm Cell board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| Malcolm Taub | Independent Director | Profile | |
| Mordechai Friedman | Independent Director | Profile | |
| Anthony Polverino | Independent Director | Profile | |
| Chen Schor | Independent Director | Profile |
How to buy Brainstorm Stock?
Before investing in Brainstorm Cell, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Brainstorm Cell. To buy Brainstorm Cell stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Brainstorm Cell. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Brainstorm Cell stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Brainstorm Cell Therapeutics stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Brainstorm Cell Therapeutics stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Brainstorm Cell Therapeutics, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Brainstorm Stock please use our How to Invest in Brainstorm Cell guide.
Already Invested in Brainstorm Cell Therapeutics?
The danger of trading Brainstorm Cell Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Brainstorm Cell is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Brainstorm Cell. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Brainstorm Cell Ther is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Brainstorm Cell Ther offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Brainstorm Cell's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Brainstorm Cell Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Brainstorm Cell Therapeutics Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Brainstorm Cell Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Complementary Tools for Brainstorm Stock analysis
When running Brainstorm Cell's price analysis, check to measure Brainstorm Cell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Brainstorm Cell is operating at the current time. Most of Brainstorm Cell's value examination focuses on studying past and present price action to predict the probability of Brainstorm Cell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Brainstorm Cell's price. Additionally, you may evaluate how the addition of Brainstorm Cell to your portfolios can decrease your overall portfolio volatility.
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum |
Is Brainstorm Cell's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Brainstorm Cell. If investors know Brainstorm will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Brainstorm Cell listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.40) | Return On Assets (2.12) | Return On Equity (11.22) |
The market value of Brainstorm Cell Ther is measured differently than its book value, which is the value of Brainstorm that is recorded on the company's balance sheet. Investors also form their own opinion of Brainstorm Cell's value that differs from its market value or its book value, called intrinsic value, which is Brainstorm Cell's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Brainstorm Cell's market value can be influenced by many factors that don't directly affect Brainstorm Cell's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Brainstorm Cell's value and its price as these two are different measures arrived at by different means. Investors typically determine if Brainstorm Cell is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Brainstorm Cell's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.